INTERVENTION 1:	Intervention	0
Herceptin© + Taxane	Intervention	1
taxane	CHEBI:36064	13-19
Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.	Intervention	2
paclitaxel	CHEBI:45863	48-58
Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal .	Intervention	3
week	UO:0000034	36-40
week	UO:0000034	100-104
INTERVENTION 2:	Intervention	4
MYL-1401O Trastuzumab + Taxane	Intervention	5
taxane	CHEBI:36064	24-30
Part 1:Myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.	Intervention	6
paclitaxel	CHEBI:45863	44-54
Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Myl 1401O( Mylan Trastuzumab) alone once every 3 weeks until DP or subject withdrawal.	Intervention	7
week	UO:0000034	36-40
week	UO:0000034	105-109
Inclusion Criteria:	Eligibility	0
Locally recurrent or MBC that is not amenable to curative surgery and/or radiation.	Eligibility	1
recurrent	HP:0031796	8-17
surgery	OAE:0000067	58-65
Documentation of HER2 gene amplification by fluorescent in situ hybridization (FISH) (as defined by a ratio >2.0) or documentation of HER2-overexpression by immunohistochemistry (IHC) (defined as IHC3+, or IHC2+ with FISH confirmation) based on the sponsor-identified central laboratory prior to randomization. Archival tumor tissue samples can be used.	Eligibility	2
gene	BAO:0000582	22-26
ratio	UO:0000190	102-107
immunohistochemistry	BAO:0000415	157-177
central	HP:0030645	268-275
tissue	UBERON:0000479	326-332
Pathologically confirmed breast cancer with at least one measurable metastatic target lesion (based on RECIST criteria, version 1.1). Bone, central nervous system (CNS), and skin lesions, as well as lesions that were irradiated, biopsied or had any form of local intervention or surgical manipulation are only to be assessed as non-target lesions.	Eligibility	3
breast cancer	DOID:1612	25-38
target	BAO:0003064	79-85
target	BAO:0003064	332-338
central nervous system	UBERON:0001017	140-162
Patients previously treated with trastuzumab or lapatinib in the adjuvant setting are allowed if metastatic disease was diagnosed at least one year after the last dose of treatment.	Eligibility	4
lapatinib	CHEBI:49603	48-57
adjuvant	CHEBI:60809	65-73
disease	DOID:4,OGMS:0000031	108-115
year	UO:0000036	143-147
Prior treatment with hormonal agents or bisphosphonates/denosumab is allowed. Bisphosphonates/denosumab can be given simultaneously with study treatment but cannot start after randomization and is considered an indication of progressive disease (PD). Hormonal agents must be discontinued prior to beginning study therapy.	Eligibility	5
progressive	HP:0003676	225-236
disease	DOID:4,OGMS:0000031	237-244
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 - 2	Eligibility	6
group	CHEBI:24433	29-34
Serum creatinine 1.5 x ULN (upper limit of normal),	Eligibility	7
creatinine	CHEBI:16737	6-16
x	LABO:0000148	21-22
Total bilirubin 1.0 x ULN (>1.0 x ULN if documented Gilbert's disease),	Eligibility	8
x	LABO:0000148	20-21
x	LABO:0000148	32-33
disease	DOID:4,OGMS:0000031	62-69
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) 2.5 x ULN,	Eligibility	9
aspartate	CHEBI:29995	0-9
alanine	CHEBI:16449	40-47
x	LABO:0000148	75-76
AST and/or ALT <1.5 x ULN if alkaline phosphatase >2.5 x ULN,	Eligibility	10
x	LABO:0000148	20-21
x	LABO:0000148	55-56
phosphatase	GO:0016791,BAO:0000295	38-49
Alkaline phosphatase >2.5 x ULN;if bone metastases present and no liver dysfunction present.	Eligibility	11
phosphatase	GO:0016791,BAO:0000295	9-20
x	LABO:0000148	26-27
present	PATO:0000467	51-58
present	PATO:0000467	84-91
liver	UBERON:0002107	66-71
Left ventricular ejection fraction (LVEF) within institutional range of normal as measured by multiple gated acquisition scan or echocardiogram.	Eligibility	12
left	HP:0012835	0-4
ejection fraction	CMO:0000180	17-34
range	LABO:0000114	63-68
Exclusion Criteria:	Eligibility	13
Prior systemic therapy in the metastatic disease setting. This includes: chemotherapy, signal transduction inhibitors (e.g., lapatinib), HER2 targeted therapy (e.g., trastuzumab), or other investigational anticancer therapy.	Eligibility	14
disease	DOID:4,OGMS:0000031	41-48
signal transduction	GO:0007165	87-106
lapatinib	CHEBI:49603	125-134
Prior treatment with neoadjuvant or adjuvant anthracyclines with a cumulative dose of doxorubicin of >400 mg/m2, epirubicin dose >800 mg/m2.	Eligibility	15
adjuvant	CHEBI:60809	24-32
adjuvant	CHEBI:60809	36-44
doxorubicin	CHEBI:28748,BAO:0000639	86-97
Patients with bone or skin as the only site of disease. Patients with skin lesions measurable by CT scans or MRI as only site of measurable disease are allowed.	Eligibility	16
site	BFO:0000029	39-43
site	BFO:0000029	121-125
disease	DOID:4,OGMS:0000031	47-54
disease	DOID:4,OGMS:0000031	140-147
ct	BAO:0002125	97-99
Surgery or radiotherapy 2 weeks preceding Day 1. Target lesions have to be outside the irradiated fields and the patient has fully recovered from surgery or radiotherapy.	Eligibility	17
surgery	OAE:0000067	0-7
surgery	OAE:0000067	146-153
radiotherapy	OAE:0000235	11-23
radiotherapy	OAE:0000235	157-169
day	UO:0000033	42-45
target	BAO:0003064	49-55
patient	HADO:0000008,OAE:0001817	113-120
Presence of unstable angina or a history of congestive heart failure according to the New York Heart Association criteria, history of myocardial infarction <1 year from randomization, clinically significant valvular disease, serious cardiac arrhythmia requiring treatment, uncontrolled hypertension or known pulmonary hypertension.	Eligibility	18
history	BFO:0000182	33-40
history	BFO:0000182	123-130
congestive heart failure	HP:0001635,DOID:6000	44-68
heart	UBERON:0000948	55-60
heart	UBERON:0000948	95-100
myocardial infarction	HP:0001658,DOID:5844	134-155
year	UO:0000036	159-163
disease	DOID:4,OGMS:0000031	216-223
arrhythmia	HP:0011675	241-251
hypertension	HP:0000822,DOID:10763	286-298
hypertension	HP:0000822,DOID:10763	318-330
pulmonary hypertension	DOID:6432	308-330
Peripheral sensory or motor neuropathy Grade 2 or higher according to the National Cancer Institute-Common Terminology Criteria (NCI-CTC) Version 4.03 [19].	Eligibility	19
peripheral	HP:0030646	0-10
neuropathy	DOID:870	28-38
cancer	DOID:162	83-89
Any other cancer, including contralateral breast cancer, within 5 years prior to screening with the exception of adequately treated ductal carcinoma in situ, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin.	Eligibility	20
cancer	DOID:162	10-16
cancer	DOID:162	49-55
breast cancer	DOID:1612	42-55
ductal carcinoma in situ	HP:0030075,DOID:0060074	132-156
carcinoma	HP:0030731,DOID:305	139-148
carcinoma	HP:0030731,DOID:305	186-195
carcinoma	HP:0030731,DOID:305	250-259
squamous cell carcinoma of the skin	HP:0006739	236-271
Immunocompromized patients, including known seropositivity for human immunodeficiency virus, or current or chronic hepatitis B and/or hepatitis C infection (as detected by positive testing for hepatitis B surface antigen or antibody to hepatitis C virus with confirmatory testing).	Eligibility	21
immunodeficiency	HP:0002721	69-85
virus	BAO:0000232	86-91
virus	BAO:0000232	248-253
chronic hepatitis	HP:0200123,DOID:2237	107-124
hepatitis b	DOID:2043	115-126
hepatitis b	DOID:2043	193-204
hepatitis c	DOID:1883	134-145
hepatitis c	DOID:1883	236-247
antigen	CHEBI:59132	213-220
antibody	GO:0042571,BAO:0000502	224-232
Complete listing of Inc/Excl. within protocol	Eligibility	22
Outcome Measurement:	Results	0
Primary Endpoint : Compare Best Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus Taxane Versus Herceptin® Plus Taxane in the ITT1 Population	Results	1
rate	BAO:0080019	49-53
week	UO:0000034	144-148
taxane	CHEBI:36064	170-176
taxane	CHEBI:36064	200-206
Tumor measurements were perform by centralized blinded reviewers using RECIST 1.1 criteria. Per RECIST 1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to <10 mm.Partial Response (PR): >/= 30% decrease sum of the diameters of target lesions from baseline sum diameters.	Results	2
target	BAO:0003064	153-159
target	BAO:0003064	305-311
lymph	UBERON:0002391	186-191
Progressive Disease (PD): </= 20% increase in the sum of the diameters of target lesions, from the smallest sum on study with at least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions* denotes disease progression.	Results	3
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
disease	DOID:4,OGMS:0000031	238-245
increase	BAO:0001251	34-42
increase	BAO:0001251	151-159
target	BAO:0003064	74-80
denotes	IAO:0000219	230-237
Stable Disease (SD): Neither sufficient decrease or increase. Evaluation of Non-Target Lesions Complete Response (CR): Disappearance of all non-target lesions. Non-complete Response/Non-Progressive Disease: Persistence of one or more non-target lesions. Progressive Disease (PD): Substantial, unequivocal progression of existing non-target lesions.	Results	4
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
disease	DOID:4,OGMS:0000031	198-205
disease	DOID:4,OGMS:0000031	266-273
increase	BAO:0001251	52-60
progressive	HP:0003676	186-197
progressive	HP:0003676	254-265
Time frame: from time of First treatment to week 24	Results	5
time	PATO:0000165	0-4
time	PATO:0000165	17-21
week	UO:0000034	44-48
Results 1:	Results	6
Arm/Group Title: Herceptin  + Taxane	Results	7
taxane	CHEBI:36064	30-36
Arm/Group Description: Part 1: Herceptin  (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.	Results	8
paclitaxel	CHEBI:45863	71-81
Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Herceptin  (trastuzumab) alone once every 3 weeks until DP or subject withdrawal .	Results	9
week	UO:0000034	36-40
week	UO:0000034	100-104
Overall Number of Participants Analyzed: 228	Results	10
Measure Type: Count of Participants	Results	11
Unit of Measure: Participants  Complete Response: 0   0.0%	Results	12
Partial Response: 146  64.0%	Results	13
Stable Disease: 49  21.5%	Results	14
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
Progressive Disease: 20   8.8%	Results	15
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
Not Evaluable: 13   5.7%	Results	16
Results 2:	Results	17
Arm/Group Title: MYL-1401O Trastuzumab + Taxane	Results	18
taxane	CHEBI:36064	41-47
Arm/Group Description: Part 1:Myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.	Results	19
paclitaxel	CHEBI:45863	67-77
Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Myl 1401O( Mylan Trastuzumab) alone once every 3 weeks until DP or subject withdrawal.	Results	20
week	UO:0000034	36-40
week	UO:0000034	105-109
Overall Number of Participants Analyzed: 230	Results	21
Measure Type: Count of Participants	Results	22
Unit of Measure: Participants  Complete Response: 3   1.3%	Results	23
Partial Response: 157  68.3%	Results	24
Stable Disease: 48  20.9%	Results	25
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
Progressive Disease: 9   3.9%	Results	26
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
Not Evaluable: 13   5.7%	Results	27
Adverse Events 1:	Adverse Events	0
Total: 91/246 (36.99%)	Adverse Events	1
Febrile Neutropenia 10/246 (4.07%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Leukopenia 12/246 (4.88%)	Adverse Events	3
leukopenia	HP:0001882,DOID:615	0-10
Neutropenia 62/246 (25.20%)	Adverse Events	4
neutropenia	HP:0001875,DOID:1227	0-11
Pancytopenia 0/246 (0.00%)	Adverse Events	5
pancytopenia	HP:0001876,DOID:12450	0-12
Thrombocytopenia 1/246 (0.41%)	Adverse Events	6
thrombocytopenia	HP:0001873,DOID:1588	0-16
Acute Myocardial Infarction 0/246 (0.00%)	Adverse Events	7
acute myocardial infarction	DOID:9408	0-27
Cardiac Failure 0/246 (0.00%)	Adverse Events	8
Carditis 0/246 (0.00%)	Adverse Events	9
Abdominal Pain 0/246 (0.00%)	Adverse Events	10
abdominal pain	HP:0002027	0-14
Anal Fissure 0/246 (0.00%)	Adverse Events	11
anal fissure	HP:0012390,DOID:3128	0-12
Diarrhoea 4/246 (1.63%)	Adverse Events	12
Adverse Events 2:	Adverse Events	13
Total: 97/247 (39.27%)	Adverse Events	14
Febrile Neutropenia 11/247 (4.45%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	8-19
Leukopenia 5/247 (2.02%)	Adverse Events	16
leukopenia	HP:0001882,DOID:615	0-10
Neutropenia 68/247 (27.53%)	Adverse Events	17
neutropenia	HP:0001875,DOID:1227	0-11
Pancytopenia 1/247 (0.40%)	Adverse Events	18
pancytopenia	HP:0001876,DOID:12450	0-12
Thrombocytopenia 0/247 (0.00%)	Adverse Events	19
thrombocytopenia	HP:0001873,DOID:1588	0-16
Acute Myocardial Infarction 1/247 (0.40%)	Adverse Events	20
acute myocardial infarction	DOID:9408	0-27
Cardiac Failure 2/247 (0.81%)	Adverse Events	21
Carditis 1/247 (0.40%)	Adverse Events	22
Abdominal Pain 1/247 (0.40%)	Adverse Events	23
abdominal pain	HP:0002027	0-14
Anal Fissure 1/247 (0.40%)	Adverse Events	24
anal fissure	HP:0012390,DOID:3128	0-12
Diarrhoea 3/247 (1.21%)	Adverse Events	25
